

- acute myeloid leukaemia in Germany. *Euro Surveill* **17**: 20262, 2012.
- 56) Mellado E, De La Camara R, Buendía B, Rodríguez-Tudela JL, Cuenca-Estrella M: Breakthrough pulmonary *Aspergillus fumigatus* infection with multiple triazole resistance in a Spanish patient with chronic myeloid leukemia. *Rev Iberoam Micol* **30**: 64–68, 2013.
 - 57) Pavie J, Lacroix C, Hermoso DG, Robin M, Ferry C, Bergeron A, Feuilhade M, Dromer F, Gluckman E, Molina JM, Ribaud P: Breakthrough disseminated *Aspergillus ustus* infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. *J Clin Microbiol* **43**: 4902–4904, 2005.
 - 58) Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA: *Aspergillus lentulus* sp. nov., a new sibling species of *A. fumigatus*. *Eukaryot Cell* **4**: 625–632, 2005.
 - 59) Boersma WG, Erjavec Z, van der Werf TS, de Vries-Hosper HG, Gouw AS, Manson WL: Bronchoscopic diagnosis of pulmonary infiltrates in granulocytopenic patients with hematologic malignancies: BAL versus PSB and PBAL. *Respir Med* **101**: 317–325, 2007.
 - 60) Shannon VR, Andersson BS, Lei X, Champlin RE, Kontoyiannis DP: Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. *Bone Marrow Transplant* **45**: 647–655, 2010.
 - 61) Sampsonas F, Kontoyiannis DP, Dickey BF, Evans SE: Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: a prospective 2-year study. *Cancer* **117**: 3424–3433, 2011.
 - 62) Cordani S, Manna A, Vignali M, Tascini C: Bronchoalveolar lavage as a diagnostic tool in patients with hematological malignancies and pneumonia. *Infez Med* **16**: 209–213, 2008.
 - 63) Kawazu M, Kanda Y, Nannya Y, Aoki K, Kurokawa M, Chiba S, Motokura T, Hirai H, Ogawa S: Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1-3)- β -D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. *J Clin Microbiol* **42**: 2733–2741, 2004.
 - 64) Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ: Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. *J Infect Dis* **190**: 641–649, 2004.
 - 65) Maertens J, Glasmacher A, Selleslag D, Ngai A, Ryan D, Layton M, Taylor A, Sable C, Kartsonis N: Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. *Clin Infect Dis* **41**: e9–14, 2005.
 - 66) Pfeiffer CD, Fine JP, Safdar N: Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. *Clin Infect Dis* **42**: 1417, 2006.
 - 67) Meersseman W, Lagrou K, Maertens J, Wijngaerden EV: Invasive aspergillosis in the intensive care unit. *Clin Infect Dis* **45**: 205–216, 2007.
 - 68) Guinea J, Jensen J, Peláez T, Gijón P, Alonso R, Rivera M, Muñoz P, Bouza E: Value of a single galactomannan determination (Platelia) for the diagnosis of invasive aspergillosis in non-hematological patients with clinical isolation of *Aspergillus* spp. *Med Mycol* **46**: 575–579, 2008.
 - 69) D'Haese J, Theunissen K, Vermeulen E, Schoemans H, De Vlieger G, Lammertijn L, Meersseman P, Meersseman W, Lagrou K, Maertens J: Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. *J Clin Microbiol* **50**: 1258, 2012.
 - 70) Husain S, Clancy CJ, Nguyen MH, Swartzentruber S, Leather H, LeMonte AM, Durkin MM, Knox KS, Hage CA, Bentsen C, Singh N, Wingard JR, Wheat LJ: Performance characteristics of the platelia *Aspergillus* enzyme immunoassay for detection of *Aspergillus* galactomannan antigen in bronchoalveolar lavage fluid. *Clin Vaccine Immunol* **15**: 1760, 2008.
 - 71) Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, Spriet I, Verbeken E, Van Wijngaerden E: Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. *Am J Respir Crit Care Med* **177**: 27–34, 2008.
 - 72) Musher B, Fredricks D, Leisenring W, Balajee SA, Smith C, Marr KA: *Aspergillus* galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. *J Clin Microbiol* **42**: 5517–5522, 2004.
 - 73) He H, Ding L, Sun B, Li F, Zhan Q: Role of galactomannan determinations in bronchoalveolar lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for the diagnosis of invasive pulmonary aspergillosis: a prospective study. *Crit Care* **16**: R138, 2012.
 - 74) Kami M, Tanaka Y, Kanda Y, Ogawa S, Masumoto T, Ohtomo K, Matsumura T, Saito T, Machida U, Kashima T, Hirai H: Computed tomographic scan of the chest, latex agglutination test and plasma (1 \rightarrow 3)- β -D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients. *Haematologica* **85**: 745–752, 2000.
 - 75) Obayashi T, Negishi K, Suzuki T, Funata N: Reappraisal of the serum (1 \rightarrow 3)- β -D-glucan assay for the diagnosis of invasive fungal infections—a study based on autopsy cases from 6 years. *Clin Infect Dis* **46**: 1864–1870, 2008.
 - 76) Metan G, Koç AN, Kaynar LG, Atalay A, Oztürk A, Eser B, Cetin M: What is the role of the (1 \rightarrow 3)- β -D-glucan assay in the screening of patients undergoing autologous haematopoietic stem-cell transplantation? *Mycoses* **56**: 34–38, 2013.

- 77) Sulahian A, Porcher R, Bergeron A, Touratier S, Raffoux E, Menotti J, Derouin F, Ribaud P: Use and limits of (1-3)- β -D-glucan assay (Fungitell), compared to galactomannan determination (Platelia *Aspergillus*), for diagnosis of invasive aspergillosis. *J Clin Microbiol* **52**: 2328-2333, 2014.
- 78) Kami M, Fukui T, Ogawa S, Kazuyama Y, Machida U, Tanaka Y, Kanda Y, Kashima T, Yamazaki Y, Hamaki T, Mori S, Akiyama H, Mutou Y, Sakamaki H, Osumi K, Kimura S, Hirai H: Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. *Clin Infect Dis* **33**: 1504-1512, 2001.
- 79) Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP: Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. *Lancet Infect Dis* **9**: 89-96, 2009.
- 80) Lopes da Silva R, Ribeiro P, Abreu N, Ferreira T, Fernandes T, Monteiro A, Costa F, Caldas J, Silva M, Carande L, Ferreira G, Conduto A, Cruz E, Sousa MH, Rodrigues AS, Costa I, Veiga J, de Sousa AB: Development of two real-time quantitative TaqMan PCR assays to detect circulating *Aspergillus fumigatus* DNA in serum. *Clin Med Insights Oncol* **4**: 81-88, 2010.
- 81) Avni T, Levy I, Sprecher H, Yahav D, Leibovici L, Paul M: Diagnostic accuracy of PCR alone compared to galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis: a systematic review. *J Clin Microbiol* **50**: 3652-3658, 2012.
- 82) Herbrecht R, Caillot D, Cordonnier C, Auvrignon A, Thiébaud A, Brethon B, Michallet M, Mahlaoui N, Bertrand Y, Preziosi P, Ruiz F, Gorin NC, Gangneux JP: Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation. *J Antimicrob Chemother* **67**: 2731-2738, 2012.
- 83) Viscoli C, Herbrecht R, Akan H, Baila L, Sonet A, Gallamini A, Giagounidis A, Marchetti O, Martino R, Meert L, Paesmans M, Ameye L, Shivaprakash M, Ullmann AJ, Maertens J: An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. Infectious Disease Group of the EORTC. *J Antimicrob Chemother* **64**: 1274-1281, 2009.
- 84) Borlenghi E, Cattaneo C, Capucci MA, Pan A, Quaresmini G, Franco F, Grazioli L, Carosi GP, Rossi G: Usefulness of the MSG/IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates. *Ann Hematol* **86**: 205-210, 2007.
- 85) Aikawa N, Kusachi S, Oda S, Takesue Y, Tanaka H: Clinical effects of micafungin, a novel echinocandin antifungal agent, on systemic fungal infections in surgery, emergency, and intensive-care medicine: evaluation using the AKOTT algorithm. *J Infect Chemother* **15**: 219-227, 2009.
- 86) Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B: Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global *Aspergillus* Study Group: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *N Engl J Med* **347**: 408-415, 2002.
- 87) Ueda K, Nannya Y, Kumano K, Hangaishi A, Takahashi T, Imai Y, Kurokawa M: Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. *Int J Hematol* **89**: 592-599, 2009.
- 88) Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A, Winter J, Tallman M, Pi J, Mehta J: Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. *Bone Marrow Transplant* **40**: 451-456, 2007.
- 89) Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D: Voriconazole therapeutic drug monitoring. *Antimicrob Agents Chemother* **50**: 1570-1572, 2006.
- 90) Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O: Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. *Clin Infect Dis* **46**: 201-211, 2008.
- 91) Okuda T, Okuda A, Watanabe N, Takao M, Takayanagi K: Retrospective serological tests for determining the optimal blood concentration of voriconazole for treating fungal infection. *Yakugaku Zasshi* **128**: 1811-1818, 2008.
- 92) Hamada Y, Seto Y, Yago K, Kuroyama M: Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis. *J Infect Chemother* **18**: 501-507, 2012.
- 93) Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V, Zembower T, Mehta J: Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. *Bone Marrow Transplant* **35**: 509-513, 2005.
- 94) Matsumoto K, Ikawa K, Abematsu K, Fukunaga N, Nishida K, Fukamizu T, Shimodozono Y, Morikawa N, Takeda Y, Yamada K: Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. *Int J Antimicrob Agents* **34**: 91-94, 2009.
- 95) Suzuki Y, Tokimatsu I, Sato Y, Kawasaki K, Sato Y, Goto T, Hashinaga K, Itoh H, Hiramatsu K, Kadota J: Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. *Clin Chim Acta* **424**: 119-122, 2013.
- 96) Kubota T, Chiba K, Ishizaki T: Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population. *Clin Pharmacol Ther* **60**: 661-666, 1996.
- 97) Narita A, Muramatsu H, Sakaguchi H, Doisaki S, Tanaka M, Hama A, Shimada A, Takahashi Y, Yoshida N, Matsumoto K, Kato K, Kudo K, Furukawa-Hibi Y, Yamada K, Kojima S: Correlation of CYP2C19 phenotype with voriconazole